Kailera Therapeutics Inc. Company Profile
NASDAQ: KLRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 10.00 0.00%
Kailera Therapeutics at a glance
Kailera Therapeutics Inc. (NASDAQ: KLRA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Waltham, MA. Kailera Therapeutics is led by Mr. Ronald C. Renaud Jr., M.B.A. and employs about 145 people. The company's shares have traded publicly since 2026.
At a market capitalization of $1.30 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0002096997, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Kailera Therapeutics do?
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Kailera Therapeutics Inc.
- Ticker
- NASDAQ: KLRA
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Ronald C. Renaud Jr., M.B.A.
- Employees
- 145
- Headquarters
- 180 Third Avenue, Waltham, MA, United States
- Phone
- 781 317 0290
- Website
- kailera.com
- IPO year
- 2026
- Market cap
- $1.30B
- SEC CIK
- 0002096997
Companies similar to Kailera Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DMRADamora Therapeutics Inc. | 20.56 | +1.58% | $1.27B | vs KLRA |
| KARDKardigan Inc. | 14.20 | +2.68% | $1.33B | vs KLRA |
| ORICOric Pharmaceuticals Inc. | 12.03 | +0.17% | $1.25B | vs KLRA |
| AAPGAscentage Pharma Group International American Depository Shares | 14.55 | -4.09% | $1.36B | vs KLRA |
| TYRATyra Biosciences Inc. | 19.97 | -2.06% | $1.37B | vs KLRA |
| ANABAnaptysBio Inc. | 46.21 | +1.23% | $1.38B | vs KLRA |
| OMEROmeros Corporation | 19.12 | +1.97% | $1.38B | vs KLRA |
| NKTRNektar Therapeutics | 40.80 | +1.34% | $1.39B | vs KLRA |